ULK1 and breast carcinoma: In conclusion, our results suggest that ISL has potential for development as a chemosensitizing agent for breast cancer due to its ability to inhibit miR-25 expression, which in turn leads to the upregulation of its target gene ULK1 and the induction of autophagic cell death, ultimately resulting in accelerated ABCG2 degradation via the lysosome pathway.